Etirinotecan pegol Uses, Dosage, Side Effects and more
Etirinotecan pegol is under investigation in clinical trial NCT01663012 (Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma).
| Trade Name | Etirinotecan pegol |
| Generic | Etirinotecan pegol |
| Etirinotecan pegol Other Names | Etirinotecan pegol |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
